Slovenia

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: Our equity view of Slovenian company Krka remains neutral, but with some upside potential since our previous analysis. Despite the company's exposure to high-growth pharmaceutical... 2011-07-08

BMI View: Despite its exposure to high-growth pharmaceutical markets, Slovenian drugmaker Krka has so far not achieved the pace of expansion expected. The company's 2010 and Q111 results... 2011-05-16

BMI View: BMI believes exposure to the pharmaceutical markets of Central and Eastern Europe (CEE) will benefit Krka's long-term growth potential. The Slovenian company is well placed... 2011-01-24

BMI View: Despite Krka reporting relatively strong financial results in first nine months of 2010, BMI believes frequent temporary bans and continuous allegations of patent infringements... 2011-01-20

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has increased. The region scored 51.6 out of 100 in BMI's Pharmaceutical &... 2011-01-13

BMI View: The key risk to pharmaceutical sales in Slovenia is the introduction of price erosion mechanisms and reforms regarding the interchangeability of drugs and advertising. While... 2010-12-21

BMI View: Establishing joint ventures between the Slovenian and Russian pharmaceutical industries will expand Russia's local production capacity and introduce new technologies to domestic... 2010-11-19

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has declined. The region scored 51.5 out of 100 in BMI's Pharmaceutical &... 2010-10-27